James H. Murray

900 total citations
18 papers, 707 citations indexed

About

James H. Murray is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, James H. Murray has authored 18 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in James H. Murray's work include Monoclonal and Polyclonal Antibodies Research (3 papers), Cancer Research and Treatments (2 papers) and Melanoma and MAPK Pathways (2 papers). James H. Murray is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (3 papers), Cancer Research and Treatments (2 papers) and Melanoma and MAPK Pathways (2 papers). James H. Murray collaborates with scholars based in United States, United Kingdom and Greece. James H. Murray's co-authors include Luzheng Xue, Aviva M. Tolkovsky, Henrik S. Olsen, Cynthia Sung, Bernardetta Nardelli, Joe Zhou, Gordon Moody, Liubov Zaritskaya, Blaire L. Osborn and Diane Healey and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

James H. Murray

18 papers receiving 677 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James H. Murray United States 11 281 238 208 109 78 18 707
S. Streit Germany 7 481 1.7× 364 1.5× 110 0.5× 78 0.7× 138 1.8× 8 823
Justine Y. Bruce United States 16 413 1.5× 329 1.4× 129 0.6× 107 1.0× 275 3.5× 73 955
Guangzhi Wang China 18 490 1.7× 160 0.7× 83 0.4× 155 1.4× 103 1.3× 49 909
Jon Smythe United Kingdom 15 329 1.2× 178 0.7× 60 0.3× 81 0.7× 89 1.1× 25 752
Jay Overholser United States 11 439 1.6× 358 1.5× 138 0.7× 186 1.7× 117 1.5× 16 767
Eva Løbner Lund Denmark 15 408 1.5× 235 1.0× 62 0.3× 72 0.7× 91 1.2× 45 753
Keiichi Aomatsu Japan 15 510 1.8× 254 1.1× 63 0.3× 54 0.5× 96 1.2× 23 817
Koichi Sakaguchi Japan 17 182 0.6× 232 1.0× 64 0.3× 65 0.6× 105 1.3× 73 680
Tohru Takashi Japan 16 312 1.1× 184 0.8× 143 0.7× 433 4.0× 76 1.0× 35 1.0k

Countries citing papers authored by James H. Murray

Since Specialization
Citations

This map shows the geographic impact of James H. Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James H. Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James H. Murray more than expected).

Fields of papers citing papers by James H. Murray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James H. Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James H. Murray. The network helps show where James H. Murray may publish in the future.

Co-authorship network of co-authors of James H. Murray

This figure shows the co-authorship network connecting the top 25 collaborators of James H. Murray. A scholar is included among the top collaborators of James H. Murray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James H. Murray. James H. Murray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Fadel, Michael G, James H. Murray, Ilaria Belluomo, et al.. (2025). Non-invasive breath testing to detect colorectal cancer: protocol for a multicentre, case–control development and validation study (COBRA2 study). BMC Cancer. 25(1). 1230–1230. 1 indexed citations
2.
Naqash, Abdul Rafeh, Melissa Moey, Nagabhishek Moka, et al.. (2022). Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program. Journal of Clinical Oncology. 40(29). 3439–3452. 48 indexed citations
3.
Murray, James H., Howard Streicher, Elad Sharon, et al.. (2021). Ocular adverse events in PD-1 and PD-L1 inhibitors. SHILAP Revista de lepidopterología. 25 indexed citations
4.
Mittra, Arjun, Abdul Rafeh Naqash, James H. Murray, et al.. (2021). Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute. The Oncologist. 26(10). e1883–e1886. 20 indexed citations
5.
Ko, Andrew H., James H. Murray, Kerry Horgan, et al.. (2016). A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology. 34(4_suppl). TPS481–TPS481. 10 indexed citations
6.
Murray, James H.. (2013). Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. Thorax. 68(12). 1180–1180. 3 indexed citations
7.
Crépin, Damien, Coralie Tugny, James H. Murray, & Christophe Aïssa. (2011). Facile and chemoselective rhodium-catalysed intramolecular hydroacylation of α,α-disubstituted 4-alkylidenecyclopropanals. Chemical Communications. 47(39). 10957–10957. 28 indexed citations
8.
Denlinger, Crystal S., Vicki L. Keedy, James M. Cleary, et al.. (2011). Abstract LB-410: Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors. Cancer Research. 71(8_Supplement). LB–410. 2 indexed citations
9.
Osborn, Blaire L., Henrik S. Olsen, Bernardetta Nardelli, et al.. (2002). Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics. 303(2). 540–548. 169 indexed citations
10.
Sung, C. S. Paik, Tom J. Parry, Todd Riccobene, et al.. (2002). Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans. PubMed. 4(2). 24–33. 23 indexed citations
11.
Xue, Luzheng, James H. Murray, & Aviva M. Tolkovsky. (2000). The Ras/Phosphatidylinositol 3-Kinase and Ras/ERK Pathways Function as Independent Survival Modules Each of Which Inhibits a Distinct Apoptotic Signaling Pathway in Sympathetic Neurons. Journal of Biological Chemistry. 275(12). 8817–8824. 134 indexed citations
12.
Hirt, Joan B., et al.. (2000). Technology and Diversity: An Impending Collision on the Information Superhighway?. NASPA Journal. 38(1). 1–17. 4 indexed citations
13.
Saleh, Mansoor N., James H. Murray, Diane Healey, et al.. (2000). Phase I Trial of the Anti–Lewis Y Drug Immunoconjugate BR96-Doxorubicin in Patients With Lewis Y–Expressing Epithelial Tumors. Journal of Clinical Oncology. 18(11). 2282–2292. 152 indexed citations
14.
Hirt, Joan B., et al.. (2000). Technology and Diversity: An Impending Collision on the Information Superhighway?. NASPA Journal. 38(1). 1 indexed citations
15.
Moffat, Frederick L., et al.. (1995). Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99m-88BV59.. PubMed. 36(5). 738–45. 15 indexed citations
16.
Durda, Paul J., et al.. (1987). Tissue distribution, immunochemical characterization, and biosynthesis of 47D10, a tumor-associated surface glycoprotein.. PubMed. 47(1). 241–50. 9 indexed citations
17.
Correa, Pelayo, et al.. (1979). Histopathology of gastric dysplasias Correlations with gastric juice chemistry. The American Journal of Surgical Pathology. 3(6). 491–500. 61 indexed citations
18.
Murray, James H., et al.. (1977). Canadian Council on Hospital Accreditation project shows clinical appraisal can be satisfying. Canadian Medical Association Journal. 116(2). 200–205. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Streit Breakdown of academic impact, for papers by Justine Y. Bruce Breakdown of academic impact, for papers by Guangzhi Wang Breakdown of academic impact, for papers by Jon Smythe Breakdown of academic impact, for papers by Jay Overholser Breakdown of academic impact, for papers by Eva Løbner Lund Breakdown of academic impact, for papers by Keiichi Aomatsu Breakdown of academic impact, for papers by Koichi Sakaguchi Breakdown of academic impact, for papers by Tohru Takashi
Rankless by CCL
2026